MARKET

ACHN

ACHN

Achillion
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.17
+0.03
+0.49%
Opening 14:36 11/22 EST
OPEN
6.18
PREV CLOSE
6.14
HIGH
6.18
LOW
6.15
VOLUME
814.77K
TURNOVER
--
52 WEEK HIGH
6.46
52 WEEK LOW
1.290
MARKET CAP
864.09M
P/E (TTM)
-11.4962
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ACHN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ACHN News

  • Moore Kuehn, PLLC Encourages Investors of SRC Energy, Inc. (SRCI), Achillion Pharmaceuticals, Inc. (ACHN), and Arotech Corporation (ARTX) to Contact Firm
  • PR Newswire.3h ago
  • Achillion's (ACHN) Danicopan Gets EMA's PRIME Tag for PNH
  • Zacks.2d ago
  • EMA grants PRIME designation to Achillion's danicopan
  • seekingalpha.3d ago
  • Achillion Pharmaceuticals Option Alert: Mar 20 $7 Calls at the Ask: 5000 @ $0.051 vs 32023 OI; Ref=$6.295
  • Benzinga.3d ago

More

Industry

Biotechnology & Medical Research
+1.64%
Pharmaceuticals & Medical Research
+0.78%

Hot Stocks

Name
Price
%Change

About ACHN

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial. The Company has discovered and advanced multiple compounds into clinical development, including sovaprevir, odalasvir, and ACH-3422 in its hepatitis C virus (HCV) program.
More

Webull offers Achillion Pharmaceuticals, Inc. (ACHN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.